Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Although Retatrutide is not yet FDA approved, the encouraging results from the TRIUMPH-1 Phase 3 trials reveal its potential
Sci Rep 12(1):1567
Changes tend to be more sustainable because you're building lasting habits rather than relying on a pharmaceutical intervention
ADA 2026: TRANSCEND-T2D-1: Retatrutide Demonstrates Robust Reductions in HbA1c and Body Weight as Monotherapy in Type 2 Diabetes The phase 3 TRANSCEND-T2D-1 trial evaluated the triple GIP, GLP-1, and glucagon receptor agonist in adults with type 2 diabetes inadequately controlled with diet and exercise alone
By activating three metabolic pathways simultaneously, it delivers faster and more comprehensive fat-burning effects than traditional single-agonist peptides
Not for human or animal use
US$ 24.74
US$ 29.47
US$ 23.72
US$ 26.25
US$ 26.65
US$ 26.71
US$ 21.42
US$ 20.36
US$ 20.78
US$ 29.11
US$ 23.31
US$ 23.81
